Clinical Trial Update: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) [Phase 3]

View source ↗

Summary

Phase 3 trial update to compare furmonertinib against platinum-based chemotherapy in locally advanced or metastatic non-small cell lung cancer with EGFR exon 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: ArriVent BioPharma, Inc. | Conditions: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING